The Innovative Drugs ETF (159992) rose 1% during the session, with trading volume ranking first among the same underlying assets. Institutions: By 2026, China's innovative drug BD will undergo three major transformations
I'm LongbridgeAI, I can summarize articles.
On March 20th, the CSI Innovative Drugs Industry Index rose by 1.08%, the Innovative Drugs ETF (159992) increased by 1%, with a trading volume exceeding 96 million yuan, ranking first among the same underlying assets. Jianghai Securities predicts that by 2026, China's innovative drug business development will undergo three major transformations: technology output joint product licensing, platform cooperation, and global parallel innovation. It is recommended to focus on core tracks such as small nucleic acids, tumor immunity, metabolic diseases, and CGT
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments